سعر ابتوفول 5/12.5 مجم 10 أقراص 2026

Aptoful 5/12.5 film-coated tablets (bisoprolol fumarate 5 mg + hydrochlorothiazide 12.5 mg), a fixed combination of a cardioselective beta-1 blocker and a thiazide diuretic for hypertension, by EIPICO, Egypt; pack of 10 tablets.

• Arterial hypertension in adults when monotherapy is insufficientPopulation: AdultsFederal Agency for Medicines and Health Products (FAMHP / FAGG-AFMPS), Belgium

• Common: dizziness, headache and fatigue (mainly at the start, usually mild and resolving within 1-2 weeks); nausea, vomiting, diarrhoea, constipation; cold or numb extremities; hyperglycaemia, hyperuricaemia, electrolyte disturbances (especially hypokalaemia and hyponatraemia); raised triglycerides and cholesterol, glucosuria. Uncommon: bradycardia, AV conduction disturbances, worsening heart failure, orthostatic hypotension, bronchospasm in asthma/COPD, depression, sleep disturbance, muscle weakness/cramps, pancreatitis. Rare/very rare: syncope, hepatitis, jaundice, leukopenia, thrombocytopenia, agranulocytosis, hypersensitivity reactions, reduced tear production. Frequency not known: non-melanoma skin cancer, choroidal effusion, interstitial lung disease.International label, same formulation · Federal Agency for Medicines and Health Products (FAMHP / FAGG-AFMPS), Belgium

• Hypersensitivity to the active substances, other thiazides, sulfonamides or any excipient; acute heart failure or decompensated heart failure needing IV inotropes; cardiogenic shock; second- or third-degree AV block (without pacemaker); sick sinus syndrome; sinoatrial block; symptomatic bradycardia; severe bronchial asthma; severe peripheral arterial occlusive disease or severe Raynaud disease; untreated phaeochromocytoma; severe renal impairment (CrCl 30 ml/min or less); severe hepatic impairment; metabolic acidosis; refractory hypokalaemia; severe hyponatraemia; hypercalcaemia; gout.International label, same formulation · Federal Agency for Medicines and Health Products (FAMHP / FAGG-AFMPS), Belgium
• US label contraindications: cardiogenic shock, overt cardiac failure, second- or third-degree AV block, marked sinus bradycardia, anuria, and hypersensitivity to either component or to other sulfonamide-derived drugs.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Do not stop bisoprolol abruptly unless clearly indicated (risk of acute deterioration, especially in ischaemic heart disease). Use with caution in concomitant heart failure, diabetes with large glucose fluctuations (hypoglycaemia symptoms may be masked; higher risk of severe hypoglycaemia with sulfonylureas), strict fasting, first-degree AV block, Prinzmetal angina, peripheral arterial occlusive disease, hypovolaemia, choroidal effusion and impaired liver function.International label, same formulation · Federal Agency for Medicines and Health Products (FAMHP / FAGG-AFMPS), Belgium
• Beta-blockers should generally be avoided in obstructive airway disease unless there are compelling reasons; if used, give with care and with concomitant bronchodilator therapy (beta-2 agonist dose may need to be increased).International label, same formulation · Federal Agency for Medicines and Health Products (FAMHP / FAGG-AFMPS), Belgium
• May increase sensitivity to allergens and severity of anaphylactic reactions (adrenaline may be less effective); psoriasis only after careful benefit-risk assessment; symptoms of thyrotoxicosis may be masked; in phaeochromocytoma give only after alpha-blockade; inform the anaesthetist (if withdrawal before surgery is needed, taper to finish about 48 hours before anaesthesia).International label, same formulation · Federal Agency for Medicines and Health Products (FAMHP / FAGG-AFMPS), Belgium

• LithiumNot recommended: reduced lithium excretion may increase its cardiotoxic and neurotoxic effects.Federal Agency for Medicines and Health Products (FAMHP / FAGG-AFMPS), Belgium
• Verapamil- and diltiazem-type calcium antagonistsNot recommended: negative effects on contractility and AV conduction; IV verapamil may cause profound hypotension and AV block.Federal Agency for Medicines and Health Products (FAMHP / FAGG-AFMPS), Belgium
• Centrally acting antihypertensives (clonidine, methyldopa, moxonidine, rilmenidine)Not recommended: further fall in heart rate and cardiac output; abrupt withdrawal (especially before the beta-blocker) may increase the risk of rebound hypertension.Federal Agency for Medicines and Health Products (FAMHP / FAGG-AFMPS), Belgium

• Not recommended during pregnancy unless the woman's clinical condition makes treatment with bisoprolol/hydrochlorothiazide necessary.International label, same formulation · Federal Agency for Medicines and Health Products (FAMHP / FAGG-AFMPS), Belgium
• Not recommended during breastfeeding: bisoprolol may and hydrochlorothiazide does pass into breast milk, and hydrochlorothiazide may reduce milk production.International label, same formulation · Federal Agency for Medicines and Health Products (FAMHP / FAGG-AFMPS), Belgium
• US label: thiazides are excreted in human milk; decide whether to discontinue nursing or the drug, considering the importance of the drug to the mother.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Bisoprolol fumarate: Highly beta-1-selective blocker without intrinsic sympathomimetic activity; blocks cardiac beta-receptors, suppressing sympathetic drive and lowering heart rate, contractility and myocardial oxygen consumption.
• Hydrochlorothiazide: Inhibits sodium (and chloride) reabsorption in the distal tubule, increasing natriuresis and potassium excretion; lowers peripheral resistance with long-term use.